Intended for licensed healthcare professionals located in the EU.
Because Tomorrows Matters Today

For adult patients with CML failing on one 2G TKI, ICLUSIG® combines experience and data to improve their futures1–3*

CML
ICLUSIG is indicated in adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315l mutation
Blue square
Also available
for your
patients with
Ph+ ALL
Ph+ ALL
ICLUSIG is indicated in adult patients with Philadelphia
chromosome positive acute lymphoblastic leukaemia
(Ph+ ALL) who are resistant to dasatinib; who are
intolerant to dasatinib and for whom subsequent
treatment with imatinib is not clinically appropriate;
or who have the T315l mutation